Allergy/Imm

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Xu J et al. – The authors demonstrate that the LXR agonist T0901317 suppressed the development of EAE in an experimental paradigm involving treatment of established EAE. Collectively, these studies suggest that LXR agonists may be effective in the treatment of MS.

Today in Rheumatic/Autoimmune...keeping you current

Update in treatment options for psoriatic arthritis
Expert Review of Clinical Immunology, 11/23/09

Adalimumab for the treatment of psoriatic arthritis
Expert Review of Clinical Immunology, 11/19/09

Functional activation of proline-rich tyrosine kinase2 (PYK2) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus
BMC Musculoskeletal Disorders, 11/18/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address